Merck KGaA to acquire Bio-Techne for $11.3 billion
- Merck KGaA, Darmstadt, Germany agreed to acquire Bio-Techne (NASDAQ:TECH) for $73 per share in cash, implying an enterprise value of $11.3 billion.
- The deal represents a 36% premium to Bio-Techne’s one-month volume-weighted average price.
- Merck KGaA expects the transaction to be immediately accretive to sales growth and EBITDA pre margin with annual cost synergies of approximately EUR 140 million by year three.
Merck KGaA, Darmstadt, Germany has agreed to acquire Bio-Techne (NASDAQ:TECH) for $73 per share in cash, implying an enterprise value of $11.3 billion.
The transaction represents a 36% premium to Bio-Techne’s one-month volume-weighted average share price.
The deal is expected to close by late 2026 or early 2027, subject to customary closing conditions including regulatory approvals, and will be funded with cash and new debt.
Merck KGaA targets annual cost synergies of approximately EUR 140 million by the third year after closing.
The company stated the acquisition is expected to be immediately accretive to sales growth and EBITDA pre margin.
Bio-Techne provides high-quality reagents, instruments, and services for the life sciences and diagnostics markets worldwide.
Frequently asked questions
More from United States
Lamar raises 2026 AFFO outlook to $8.97
Lemonade posts $336 million Q3 revenue, narrows loss
BD reveals $5.27 billion Q4 revenue, raises 2027 outlook
Cummins earnings surge to $1.14 billion as sales climb 13%
Six Flags reveals $1.17 billion Q3 revenue amid $366 million loss
EPAM Systems reports $1.43B Q3 revenue, expands buyback to $1.8B
